Physician-Prescribed · 503A Pharmacy Compounded
Hit a wall on semaglutide or tirzepatide? Retatrutide is built for the plateau.
Direct Reta connects you with a licensed physician who can prescribe retatrutide — triple-hormone therapy compounded to your exact dose by a U.S. 503A pharmacy. Real prescription. Real oversight. Not a research-use-only vial from an unregulated vendor.
- Receptors
- GIP + GLP-1 + Glucagon
- Source
- US 503A Pharmacy
- Dosing
- 1–8 mg titration
How Direct Reta works
No grey-market vials, no guesswork. Just a licensed medical process from consult to delivery.
Complete your intake
Tell us about your health history and weight-loss goals — including any semaglutide or tirzepatide you've already tried.
Meet with a licensed physician
An independent, licensed provider reviews your case and determines whether retatrutide is appropriate for you.
Compounded and shipped
If prescribed, your medication is compounded to your exact dose by a licensed U.S. 503A pharmacy and shipped directly to you, temperature-controlled.
Ongoing clinical support
Your care team monitors your progress and adjusts your titration plan — the same way your dose was managed before.
Why patients plateau on semaglutide and tirzepatide
Semaglutide works through a single hormone pathway, GLP-1. Tirzepatide adds a second, GIP. As the body adapts, weight loss can level off even at the highest approved doses. Retatrutide is an investigational triple agonist that adds a third mechanism, glucagon receptor activity, associated with increased energy expenditure — designed for patients whose results plateaued on a single- or dual-agonist therapy.
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptor targets | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Mechanism | Appetite suppression, slowed gastric emptying | Appetite suppression + improved insulin sensitivity | Appetite suppression + insulin sensitivity + increased energy expenditure via glucagon activity |
| Typically prescribed after | First-line GLP-1 therapy | Semaglutide plateau or insufficient response | Tirzepatide plateau, or patients seeking a third mechanism of action |
Retatrutide is an investigational compound; clinical trials are ongoing. Individual results vary and are not guaranteed. This is not a claim of superiority backed by head-to-head trial data.
The clinical evidence
Retatrutide's Phase 3 results, in Eli Lilly's own trial data
Retatrutide is still investigational and not yet FDA-approved — but it has been studied in a 2,339-person randomized, placebo-controlled Phase 3 trial (TRIUMPH-1).1
Average weight loss at 80 weeks (12 mg, Phase 3 TRIUMPH-1)
Average weight loss at 80 weeks (9 mg, Phase 3 TRIUMPH-1)
Average weight loss at 80 weeks (4 mg, Phase 3 TRIUMPH-1)
Why a third receptor matters
In preclinical research, retatrutide's glucagon receptor activity was associated with increased energy expenditure — a mechanism GLP-1-only and GLP-1/GIP therapies don't have.2 That's the biological rationale behind offering it to patients whose progress has slowed on other therapies, though individual response varies and isn't guaranteed.
Safety & side effects
In the TRIUMPH-1 trial, the most common side effects at the 12 mg dose were nausea (42.4% vs. 14.8% placebo), diarrhea (32.0% vs. 13.5% placebo), and constipation (26.1% vs. 10.9% placebo). 11.3% of participants on 12 mg discontinued due to adverse events, versus 4.9% on placebo.1 Your prescribing physician will review your full medical history before determining whether retatrutide is appropriate for you.
- 1. Eli Lilly and Company, TRIUMPH-1 Phase 3 topline results news release, 2026.
- 2. Coskun, T. et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.” Cell Metabolism, 2022.
Why it matters
Not a “research use only” vial. A real prescription.
Most retatrutide sold online today is labeled “research use only” (RUO) — sold by peptide vendors with no prescription, no physician, and no pharmacy-grade quality control. The FDA has issued warning letters making clear that an RUO label doesn't exempt a product from drug law when it's actually being sold for people to inject. Direct Reta works differently: every order starts with a licensed physician and is compounded by a licensed U.S. 503A pharmacy under federal sterile-compounding standards.
| Direct Reta | Grey-market RUO | |
|---|---|---|
| Requires a prescription | ||
| Licensed physician reviews your health history | ||
| Compounded under USP <797> sterile compounding standards | ||
| Potency & sterility tested before it ships | ||
| Made in an FDA-registered compounding facility | ||
| Legally labeled "not for human consumption" |
Source: FDA guidance on research-use-only labeling and drug law; USP General Chapters <797> (sterile compounding) and <71> (sterility testing).
One prescription, five doses, one titration plan
Your physician selects and adjusts your dose over time — the same titration approach used with semaglutide and tirzepatide, extended across a wider range built for patients who need more.
Includes your physician consultation, prescription, compounded medication shipped from a licensed 503A pharmacy, and ongoing clinical support. Final pricing depends on dose and plan.
Check Your EligibilityFrequently asked questions
Is retatrutide legal?+
Retatrutide itself is still investigational and does not yet have FDA approval as a standalone branded drug. What Direct Reta provides is legal, licensed compounding: a U.S.-licensed physician evaluates you and, if appropriate, writes a patient-specific prescription, which our partner 503A pharmacy compounds under FDA-regulated compounding rules. That's fundamentally different from buying "research use only" peptides online with no prescription and no clinician involved.
How is this different from the research-use-only (RUO) retatrutide I see online?+
RUO vials are sold without a prescription, without a physician evaluating your health history, and without pharmacy-grade quality controls — they are legally labeled "not for human consumption." Direct Reta's process starts with a licensed physician and ends with medication compounded by a licensed 503A pharmacy specifically for you, with sterility and potency testing built into the compounding process.
I've plateaued on semaglutide or tirzepatide. Will retatrutide help?+
Every patient is different, and your physician will evaluate your specific history. Retatrutide adds a third mechanism (glucagon receptor agonism) on top of the GLP-1 and GIP pathways targeted by semaglutide and tirzepatide, which is why it's being studied specifically in patients looking for effects beyond what dual or single-agonist therapy achieved for them.
What does the process cost, and what's included?+
Plans start at $199/mo and include your physician consultation, prescription, compounded medication, and ongoing clinical support. Your exact price depends on your prescribed dose and plan.
How is my medication shipped?+
Once prescribed, your medication ships directly from our partner 503A pharmacy in temperature-controlled packaging, discreetly, to your door.
Can I cancel or change my plan?+
Yes. You can adjust your plan or cancel at any time by contacting your care team — there's no long-term contract.